# A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

> **NCT07743463** · PHASE3 · RECRUITING · sponsor: **Ascletis Pharma (China) Co., Limited** · enrollment: 3003 (estimated)

## Conditions studied

- Obesity
- Overweight
- Chronic Weight Management

## Interventions

- **DRUG:** ASC30 tablets A1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07743463
- **Lead sponsor:** Ascletis Pharma (China) Co., Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 3003 (ESTIMATED)
- **Last updated:** 2026-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743463, "A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*